Schwetz Verena, Trummer Christian, Pandis Marlene, Grübler Martin R, Verheyen Nicolas, Gaksch Martin, Zittermann Armin, März Winfried, Aberer Felix, Lang Angelika, Treiber Gerlies, Friedl Claudia, Obermayer-Pietsch Barbara, Pieber Thomas R, Tomaschitz Andreas, Pilz Stefan
Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz 8036, Austria.
Swiss Cardiovascular Center Bern, Department of Cardiology, Bern University Hospital, University of Bern, Bern 3011, Switzerland.
Nutrients. 2017 Apr 27;9(5):432. doi: 10.3390/nu9050432.
Bone turnover markers (BTMs) are used to evaluate bone health together with bone mineral density and fracture assessment. Vitamin D supplementation is widely used to prevent and treat musculoskeletal diseases but existing data on vitamin D effects on markers of bone resorption and formation are inconsistent. We therefore examined the effects of vitamin D supplementation on bone-specific alkaline phosphatase (bALP), osteocalcin (OC), C-terminal telopeptide (CTX), and procollagen type 1 N-terminal propeptide (P1NP). This is a post-hoc analysis of the Styrian Vitamin D Hypertension Trial, a single-center, double-blind, randomized, placebo-controlled trial (RCT) performed at the Medical University of Graz, Austria (2011-2014). Two hundred individuals with arterial hypertension and 25-hydroxyvitamin D (25[OH]D) levels <75 nmol/L were randomized to 2800 IU of vitamin D daily or placebo for eight weeks. One hundred ninety-seven participants (60.2 ± 11.1 years; 47% women) were included in this analysis. Vitamin D had no significant effect on bALP (mean treatment effect (MTE) 0.013, 95% CI -0.029 to 0.056 µg/L; = 0.533), CTX (MTE 0.024, 95% CI -0.163 to 0.210 ng/mL, = 0.802), OC (MTE 0.020, 95% CI -0.062 to 0.103 ng/mL, = 0.626), or P1NP (MTE -0.021, 95% CI -0.099 to 0.057 ng/mL, = 0.597). Analyzing patients with 25(OH)D levels <50 nmol/L separately ( = 74) left results largely unchanged. In hypertensive patients with low 25(OH)D levels, we observed no significant effect of vitamin D supplementation for eight weeks on BTMs.
骨转换标志物（BTMs）与骨矿物质密度和骨折评估一起用于评估骨骼健康。补充维生素D被广泛用于预防和治疗肌肉骨骼疾病，但现有关于维生素D对骨吸收和形成标志物影响的数据并不一致。因此，我们研究了补充维生素D对骨特异性碱性磷酸酶（bALP）、骨钙素（OC）、C端肽（CTX）和I型前胶原N端前肽（P1NP）的影响。这是对施蒂里亚维生素D高血压试验的事后分析，该试验是在奥地利格拉茨医科大学进行的一项单中心、双盲、随机、安慰剂对照试验（RCT）（2011 - 2014年）。200名动脉高血压患者且25 - 羟基维生素D（25[OH]D）水平<75 nmol/L被随机分为每日服用2800 IU维生素D或安慰剂，为期8周。197名参与者（60.2±11.1岁；47%为女性）被纳入该分析。维生素D对bALP（平均治疗效果（MTE）0.013，95%可信区间 - 0.029至0.056 μg/L；P = 0.533）、CTX（MTE 0.024，95%可信区间 - 0.163至0.210 ng/mL，P = 0.802）、OC（MTE 0.020，95%可信区间 - 0.062至0.103 ng/mL，P = 0.626）或P1NP（MTE - 0.021，95%可信区间 - 0.099至0.057 ng/mL，P = 0.597）均无显著影响。单独分析25(OH)D水平<50 nmol/L的患者（n = 74），结果基本不变。在25(OH)D水平较低的高血压患者中，我们观察到补充维生素D 8周对骨转换标志物无显著影响。
